Ursula Wiedermann

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3018874/publications.pdf

Version: 2024-02-01

168	4,850	81900	133252
papers	citations	39 h-index	59 g-index

185	185	185	4983
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH₂ to TH₁ in Tâ€cell clones specific for Phi p 1, a major grass pollen allergen. Clinical and Experimental Allergy, 1997, 27, 1007-1015.	2.9	288
2	Bet v 1, the major birch pollen allergen, and Mal d 1, the major apple allergen, cross-react at the level of allergen-specific T helper cellsâ˜†â˜†â˜†â˜…â˜…â˜…. Journal of Allergy and Clinical Immunology, 1998, 102, 679-686.	2.9	119
3	Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Lancet, The, 2018, 392, 2718-2727.	13.7	116
4	Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine, 2003, 22, 87-95.	3.8	114
5	Primary vaccine failure to routine vaccines: Why and what to do?. Human Vaccines and Immunotherapeutics, 2016, 12, 239-243.	3.3	110
6	Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling. Scientific Reports, 2019, 9, 11472.	3.3	109
7	Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 812-819.	5.7	101
8	A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study. Breast Cancer Research and Treatment, 2010, 119, 673-683.	2.5	99
9	Vaccination of healthcare personnel in Europe: Update to current policies. Vaccine, 2019, 37, 7576-7584.	3.8	86
10	A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. Journal of Allergy and Clinical Immunology, 2005, 115, 1010-1016.	2.9	83
11	VITAMIN A DEFICIENCY INCREASES INFLAMMATORY RESPONSES. Scandinavian Journal of Immunology, 1996, 44, 578-584.	2.7	82
12	Nonâ€anaphylactic surfaceâ€exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clinical and Experimental Allergy, 2004, 34, 1525-1533.	2.9	82
13	Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules. Scientific Reports, 2018, 8, 9825.	3.3	72
14	High-Affinity IgE Receptors on Dendritic Cells Exacerbate Th2-Dependent Inflammation. Journal of Immunology, 2011, 187, 164-171.	0.8	71
15	Impaired mucosal antibody response to cholera toxin in vitamin A-deficient rats immunized with oral cholera vaccine. Infection and Immunity, 1993, 61, 3952-3957.	2.2	69
16	Aberrant T-cell function in vitro and impaired T-cell dependent antibody response in vivo in vitamin A-deficient rats. Immunology, 1993, 80, 581-6.	4.4	69
17	Potential and Opportunities for Use of Recombinant Lactic Acid Bacteria in Human Health. Advances in Applied Microbiology, 2004, 56, 1-64.	2.4	67
18	Suppression of antigen-specific T- and B-cell responses by intranasal or oral administration of recombinant Bet v 1, the major birch pollen allergen, in a murine model of type I allergy. Journal of Allergy and Clinical Immunology, 1999, 103, 1202-1210.	2.9	66

#	Article	IF	Citations
19	Vitamin A deficiency predisposes to Staphylococcus aureus infection. Infection and Immunity, 1996, 64, 209-214.	2.2	64
20	Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1. Clinical and Experimental Immunology, 1997, 107, 536-541.	2.6	63
21	Allergen mimotopes in food enhance type I allergic reactions in mice. FASEB Journal, 1999, 13, 1586-1592.	0.5	63
22	Generation of an Allergy Vaccine by Disruption of the Three-Dimensional Structure of the Cross-Reactive Calcium-Binding Allergen, Phl p 7. Journal of Immunology, 2004, 172, 5684-5692.	0.8	62
23	Oligodeoxynucleotides containing CpG motifs modulate the allergic TH2 response of BALB/c mice to Bet v 1, the major birch pollen allergenâ˜†â˜†â˜†.... Journal of Allergy and Clinical Immunology, 1999, 104, 1015-1023.	2.9	61
24	Intranasal Treatment with a Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1 Prevents Allergic Sensitization and Airway Inflammation in Mice. International Archives of Allergy and Immunology, 2001, 126, 68-77.	2.1	55
25	Animal models of type I allergy using recombinant allergens. Methods, 2004, 32, 271-280.	3.8	51
26	Effects of adjuvants on the immune response to allergens in a murine model of allergen inhalation: cholera toxin induces a Th1-like response to Bet v 1, the major birch pollen allergen. Clinical and Experimental Immunology, 1998, 111, 144-151.	2.6	50
27	Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine, 2007, 25, 927-931.	3.8	50
28	Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. International Journal of Cancer, 2003, 107, 976-983.	5.1	49
29	Tick-Borne Encephalitis (TBE) and Hepatitis B Nonresponders Feature Different Immunologic Mechanisms in Response to TBE and Influenza Vaccination with Involvement of Regulatory T and B Cells and IL-10. Journal of Immunology, 2013, 191, 2426-2436.	0.8	48
30	Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice. Clinical and Experimental Allergy, 2002, 32, 30-36.	2.9	47
31	Vaccination with a Human High Molecular Weight Melanoma-Associated Antigen Mimotope Induces a Humoral Response Inhibiting Melanoma Cell Growth In Vitro. Journal of Immunology, 2005, 174, 976-982.	0.8	46
32	Antibody persistence following booster vaccination against tick-borne encephalitis: 3-Year post-booster follow-up. Vaccine, 2007, 25, 5097-5101.	3.8	45
33	Carbohydrate-based particles reduce allergic inflammation in a mouse model for cat allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 518-526.	5.7	45
34	Neonatal colonization of mice with Lactobacillus plantarum producing the aeroallergen Bet v 1 biases towards Th1 and T-regulatory responses upon systemic sensitization. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 368-375.	5.7	43
35	Factors associated with seroimmunity against tick borne encephalitis virus 10 years after booster vaccination. Vaccine, 2013, 31, 1293-1297.	3.8	43
36	Germ-Free Mice Exhibit Mast Cells With Impaired Functionality and Gut Homing and Do Not Develop Food Allergy. Frontiers in Immunology, 2019, 10, 205.	4.8	43

#	Article	IF	Citations
37	Rapid production of the major birch pollen allergen Bet v 1 in Nicotiana benthamiana plants and its immunological in vitro and in vivo characterization. FASEB Journal, 2000, 14, 1279-1288.	0.5	42
38	Allergenâ€specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of Vespula vulgaris venom, in a murine model of wasp venom allergy. Immunology, 2003, 110, 376-385.	4.4	42
39	The role of Foxp3+ T cells in longâ€term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 173-180.	5.7	41
40	Rapid production of the major birch pollen allergen Bet v 1 in Nicotiana benthamiana plants and its immunological in vitro and in vivo characterization. FASEB Journal, 2000, 14, 1279-1288.	0.5	40
41	Carbohydrateâ€based particles: a new adjuvant for allergenâ€specific immunotherapy. Immunology, 2002, 107, 523-529.	4.4	40
42	Travelerâ€™s Diarrhea. Infectious Disease Clinics of North America, 2012, 26, 691-706.	5.1	40
43	Influence of the route of sensitization on local and systemic immune responses in a murine model of type I allergy. Clinical and Experimental Immunology, 2004, 137, 12-18.	2.6	39
44	Intranasal tolerance induction with polypeptides derived from 3 noncross-reactive major aeroallergens prevents allergic polysensitization in mice. Journal of Allergy and Clinical Immunology, 2005, 116, 370-376.	2.9	39
45	A recombinant allergen chimer as novel mucosal vaccine candidate for prevention of multi-sensitivities. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 33-41.	5.7	39
46	Distinctive anti-allergy properties of two probiotic bacterial strains in a mouse model of allergic poly-sensitization. Vaccine, 2011, 29, 1981-1990.	3.8	38
47	Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy. International Immunology, 1999, 11, 1131-1138.	4.0	37
48	Passive immunization with allergen-specific IgG antibodies for treatment and prevention of allergy. Immunobiology, 2013, 218, 884-891.	1.9	37
49	Perinatal Maternal Administration of Lactobacillus paracasei NCC 2461 Prevents Allergic Inflammation in a Mouse Model of Birch Pollen Allergy. PLoS ONE, 2012, 7, e40271.	2.5	37
50	Phage-displayed Bet mim 1, a mimotope of the major birch pollen allergen Bet v 1, induces B cell responses to the natural antigen using bystander T cell help. Clinical and Experimental Allergy, 2002, 32, 1583-1588.	2.9	36
51	Lactic acid bacteria as novel adjuvant systems for prevention and treatment of atopic diseases. Current Opinion in Allergy and Clinical Immunology, 2008, 8, 557-564.	2.3	36
52	Booster vaccinations against tick-borne encephalitis: 6 Years follow-up indicates long-term protection. Vaccine, 2009, 27, 7027-7030.	3.8	36
53	Neonatal colonization of germ-free mice with Bifidobacterium longum prevents allergic sensitization to major birch pollen allergen Bet v 1. Vaccine, 2013, 31, 5405-5412.	3.8	36
54	Expression of the B subunit of the heat-labile enterotoxin of Escherichia coli in tobacco mosaic virus-infected Nicotiana benthamiana plants and its characterization as mucosal immunogen and adjuvant. Journal of Immunological Methods, 2004, 287, 203-215.	1.4	35

#	Article	IF	Citations
55	Immunoregulation by Toxoplasma gondii infection prevents allergic immune responses in mice. International Journal for Parasitology, 2009, 39, 465-472.	3.1	35
56	Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines. Breast Cancer Research and Treatment, 2013, 138, 1-12.	2.5	33
57	Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy. International Immunology, 1999, 11, 1717-1724.	4.0	31
58	Induction of mucosal tolerance with recombinant Hev b 1 and recombinant Hev b 3 for prevention of latex allergy in BALB/c mice. Clinical and Experimental Immunology, 2003, 133, 170-176.	2.6	29
59	Circulation of pertussis and poor protection against diphtheria among middle-aged adults in 18 European countries. Nature Communications, 2021, 12, 2871.	12.8	29
60	Increased translocation of Escherichia coli and development of arthritis in vitamin A-deficient rats. Infection and Immunity, 1995, 63, 3062-3068.	2.2	29
61	Vitamin A deficiency leads to severe functional disturbance of the intestinal epithelium enzymes associated with diarrhoea and increased bacterial translocation in gnotobiotic rats. Microbes and Infection, 2003, 5, 405-411.	1.9	28
62	Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody. International Journal of Cancer, 2005, 114, 426-432.	5.1	28
63	E. coli Nissle 1917 is a safe mucosal delivery vector for a birch-grass pollen chimera to prevent allergic poly-sensitization. Mucosal Immunology, 2019, 12, 132-144.	6.0	28
64	Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide. BMC Cancer, 2017, 17, 118.	2.6	27
65	Targeted COVID-19 Vaccination (TAV-COVID) Considering Limited Vaccination Capacitiesâ€"An Agent-Based Modeling Evaluation. Vaccines, 2021, 9, 434.	4.4	27
66	Edible genetically modified microorganisms and plants for improved health. Current Opinion in Biotechnology, 2001, 12, 510-515.	6.6	26
67	Monovalent fusion proteins of immunoglobulin E mimotopes are safe for therapy of type I allergy. FASEB Journal, 2001, 15, 2524-2526.	0.5	26
68	Prophylaxis and Therapy of Allergy by Mucosal Tolerance Induction with Recombinant Allergens or Allergen Constructs. Inflammation and Allergy: Drug Targets, 2005, 4, 577-583.	3.1	26
69	Use of a genetic cholera toxin B subunit/allergen fusion molecule as mucosal delivery system with immunosuppressive activity against Th2 immune responses. Vaccine, 2007, 25, 8395-8404.	3.8	26
70	Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice. Breast Cancer Research and Treatment, 2007, 106, 29-38.	2.5	25
71	Correlation between humoral and cellular immune responses and the expression of the hepatitis A receptor HAVcr-1 on T cells after hepatitis A re-vaccination in high and low-responder vaccinees. Vaccine, 2009, 27, 197-204.	3.8	25
72	Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program. PLoS ONE, 2019, 14, e0210081.	2.5	25

#	Article	IF	Citations
73	Rapid Production of Recombinant Allergens in Nicotiana benthamiana and Their Impact on Diagnosis and Therapy. International Archives of Allergy and Immunology, 2001, 124, 48-50.	2.1	24
74	SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients â€“ A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease. Frontiers in Immunology, 2022, 13, .	4.8	24
75	Pretravel Consultation: Rapid Dipstick Test as a Decision Guidance for the Application of Tetanus Booster Vaccinations. Journal of Travel Medicine, 2008, 15, 437-441.	3.0	23
76	Oesophagostomum dentatum Extract Modulates T Cell-Dependent Immune Responses to Bystander Antigens and Prevents the Development of Allergy in Mice. PLoS ONE, 2013, 8, e67544.	2.5	23
77	Obesity and Sex Affect the Immune Responses to Tick-Borne Encephalitis Booster Vaccination. Frontiers in Immunology, 2020, 11, 860.	4.8	23
78	Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancerâ€"Results from Phase Ib Trial IMU.ACS.001. Clinical Cancer Research, 2021, 27, 3649-3660.	7.0	23
79	Mucosal Tolerance Induction with Hypoallergenic Molecules in a Murine Model of Allergic Asthma. International Archives of Allergy and Immunology, 2001, 124, 391-394.	2.1	22
80	Prime-Boost Vaccination with Toxoplasma Lysate Antigen, but Not with a Mixture of Recombinant Protein Antigens, Leads to Reduction of Brain Cyst Formation in BALB/c Mice. PLoS ONE, 2015, 10, e0126334.	2.5	21
81	Mandatory vaccination: suited to enhance vaccination coverage in Europe?. Eurosurveillance, 2019, 24, .	7.0	21
82	Active hospital-based surveillance of rotavirus diarrhea in Austrian children, period 1997 to 2003. Wiener Klinische Wochenschrift, 2006, 118, 280-285.	1.9	20
83	Susceptibility to nasal and oral tolerance induction to the major birch pollen allergen Bet v 1 is not dependent on the presence of the microflora. Immunology Letters, 2008, 117, 50-56.	2.5	20
84	Comparable immune responsiveness but increased reactogenicity after subcutaneous versus intramuscular administration of tick borne encephalitis (TBE) vaccine. Vaccine, 2016, 34, 2027-2034.	3.8	20
85	Reduction of Human Melanoma Tumor Growth in Severe Combined Immunodeficient Mice by Passive Transfer of Antibodies Induced by a High Molecular Weight Melanoma-Associated Antigen Mimotope Vaccine. Clinical Cancer Research, 2008, 14, 8178-8183.	7.0	19
86	Universal Mass Vaccination Against Rotavirus: Indirect Effects on Rotavirus Infections in Neonates and Unvaccinated Young Infants Not Eligible for Vaccination. Journal of Infectious Diseases, 2016, 214, 546-555.	4.0	19
87	Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults. Communications Medicine, 2021, 1, .	4.2	19
88	The European LABDEL project and its relevance to the prevention and treatment of allergies. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 1237-1242.	5.7	18
89	A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors. Frontiers in Immunology, 2020, 11, 895.	4.8	18
90	Vaccination against Her-2/neu, with focus on peptide-based vaccines. ESMO Open, 2022, 7, 100361.	4.5	18

#	Article	IF	Citations
91	Genetic Variation of Bordetella pertussis in Austria. PLoS ONE, 2015, 10, e0132623.	2.5	17
92	Towards understanding vaccine hesitancy and vaccination refusal in Austria. Wiener Klinische Wochenschrift, 2021, 133, 703-713.	1.9	17
93	Airway inflammation induced after allergic polyâ€sensitization can be prevented by mucosal but not by systemic administration of polyâ€peptides. Clinical and Experimental Allergy, 2008, 38, 1192-1202.	2.9	16
94	Vaccine based on folded receptor binding domainâ€PreS fusion protein with potential to induce sterilizing immunity to SARSâ€CoVâ€2 variants. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2431-2445.	5.7	16
95	<scp>NKG2A</scp>â€checkpoint inhibition and its blockade critically depends on peptides presented by its ligand <scp>HLAâ€E</scp>. Immunology, 2022, 166, 507-521.	4.4	15
96	IgE Mimotopes of Birch Pollen Allergen Bet v 1 Induce Blocking IgG in Mice. International Archives of Allergy and Immunology, 2001, 124, 395-397.	2.1	14
97	Allergen hybrids â€“ next generation vaccines for <scp>F</scp>agales pollen immunotherapy. Clinical and Experimental Allergy, 2014, 44, 438-449.	2.9	14
98	Toxoplasma gondii tachyzoite-extract acts as a potent immunomodulator against allergic sensitization and airway inflammation. Scientific Reports, 2017, 7, 15211.	3.3	14
99	Emerging targets for anticancer vaccination: PD-1. ESMO Open, 2021, 6, 100278.	4.5	14
100	Vaccines against traveler's diarrhoea and rotavirus disease â€“ a review. Wiener Klinische Wochenschrift, 2006, 118, 2-8.	1.9	13
101	Persistence of antibodies in 4â€“8 year old Austrian children after vaccination with hexavalent DTaPâ€“HBVâ€“IPV/Hib and MMR vaccines. Vaccine, 2011, 29, 5130-5136.	3.8	13
102	Early Dietary Influence on Later Immunocompetence. Nutrition Reviews, 2009, 54, S23-S30.	5.8	12
103	Murine models for mucosal tolerance in allergy. Seminars in Immunology, 2017, 30, 12-27.	5.6	12
104	Allergic patients with and without allergen-specific immunotherapy mount protective immune responses to tick-borne encephalitis vaccination in absence of enhanced side effects or propagation of their Th2 bias. Vaccine, 2018, 36, 2816-2824.	3.8	12
105	Thioredoxin from the Indianmeal Moth Plodia interpunctella: Cloning and Test of the Allergenic Potential in Mice. PLoS ONE, 2012, 7, e42026.	2.5	12
106	Mucosal Immunity - Mucosal Tolerance. , 2003, 82, 11-24.		11
107	Epitope-Specific Antibody Response to Mel-CAM Induced by Mimotope Immunization. Journal of Investigative Dermatology, 2005, 124, 125-131.	0.7	11
108	Machine Learning-Empowered FTIR Spectroscopy Serum Analysis Stratifies Healthy, Allergic, and SIT-Treated Mice and Humans. Biomolecules, 2020, 10, 1058.	4.0	11

#	Article	IF	Citations
109	Sensitization and development of tolerance via the gut. Pediatric Allergy and Immunology, 1993, 4, 16-20.	2.6	10
110	Tick borne encephalitis TBE â€“ Vaccination in non-endemic countries. Travel Medicine and Infectious Disease, 2010, 8, 251-256.	3.0	10
111	Prophylactic and therapeutic inhibition of allergic airway inflammation by probiotic Escherichia coli O83. Journal of Allergy and Clinical Immunology, 2018, 142, 1987-1990.e7.	2.9	10
112	Prevention of Birch Pollen-Related Food Allergy by Mucosal Treatment with Multi-Allergen-Chimers in Mice. PLoS ONE, 2012, 7, e39409.	2.5	10
113	Modulation of an Allergic Immune Response via the Mucosal Route in a Murine Model of Inhalative Typeâ€“I Allergy. International Archives of Allergy and Immunology, 1999, 118, 129-132.	2.1	9
114	Travellers' diarrhoea â€“ pros and cons of different prophylactic measures. Wiener Klinische Wochenschrift, 2009, 121, 13-18.	1.9	9
115	Sensitivity of Plasmodium vivax to chloroquine, mefloquine, artemisinin and atovaquone in north-western Thailand. Wiener Klinische Wochenschrift, 2011, 123, 20-25.	1.9	9
116	Characteristics of invasive pneumococcal disease in hospitalized children in Austria. European Journal of Pediatrics, 2014, 173, 469-476.	2.7	8
117	Oocyst-Derived Extract of Toxoplasma Gondii Serves as Potent Immunomodulator in a Mouse Model of Birch Pollen Allergy. PLoS ONE, 2016, 11, e0155081.	2.5	8
118	T-cell-independent and T-cell-dependent IgE responses to the nematode Nippostrongylus brasiliensis: comparison of serum IgE and mast-cell-bound IgE. Immunology, 1995, 86, 351-5.	4.4	8
119	Effects of Breastfeeding on the Baby and on Its Immune System. Food and Nutrition Bulletin, 1996, 17, 1-5.	1.4	7
120	Synergism between mefloquine and artemisinin and its enhancement by retinol in Plasmodium falciparum in vitro. Wiener Klinische Wochenschrift, 2010, 122, 57-60.	1.9	7
121	A novel 5-Plex qPCR-HRM assay detecting human diarrheal parasites. Gut Pathogens, 2020, 12, 27.	3.4	7
122	Validation of a novel FRET real-time PCR assay for simultaneous quantitative detection and discrimination of human Plasmodium parasites. PLoS ONE, 2021, 16, e0252887.	2.5	7
123	Absent antibody production following COVID19 vaccination with mRNA in patients under immunosuppressive treatments. Vaccine, 2021, 39, 7375-7378.	3.8	7
124	Immunologically relevant aspects of the new COVID-19 vaccinesâ€"an Ã–GAIÂ(Austrian Society for) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Allergo Journal International, 2021, 30, 155-168.	2.0	6
125	Reduced seroprevalence against vaccine preventable diseases (VPDs) in adult patients with cancer: necessity of routine vaccination as part of the therapeutic concept. Annals of Oncology, 2020, 31, 319-321.	1.2	6
126	The Role of Alveolar Epithelial Type II-Like Cells in Uptake of Structurally Different Antigens and in Polarisation of Local Immune Responses. PLoS ONE, 2015, 10, e0124777.	2.5	6

#	Article	IF	Citations
127	Seroprotection 4 years following booster vaccination against tick-borne encephalitis. International Journal of Medical Microbiology, 2008, 298, 305-308.	3.6	5
128	The zinc-finger transcription factor MAZR regulates iNKT cell subset differentiation. Cellular and Molecular Life Sciences, 2019, 76, 4391-4404.	5.4	5
129	Pre- and Neonatal Imprinting on Immunological Homeostasis and Epithelial Barrier Integrity by Escherichia coli Nissle 1917 Prevents Allergic Poly-Sensitization in Mice. Frontiers in Immunology, 2020, 11, 612775.	4.8	5
130	Answers to burning questions for clinical allergologists related to the new COVID-19 vaccines. Allergo Journal International, 2021, 30, 169-175.	2.0	5
131	Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model. Translational Oncology, 2022, 19, 101378.	3.7	5
132	New allergy intervention strategies: hitting the mucosal road. Clinical and Experimental Allergy, 2007, 37, 473-475.	2.9	4
133	Tetanus Immunity in Neonates in a Developed Country. Neonatology, 2011, 100, 52-56.	2.0	4
134	Allergy and worms: letâ€™s bring back old friends?. Wiener Medizinische Wochenschrift, 2014, 164, 382-391.	1.1	4
135	Paediatricians require more information before they routinely coâ€administer the meningococcal B vaccine with routine infant vaccines. Acta Paediatrica, International Journal of Paediatrics, 2015, 104, e439-47.	1.5	4
136	Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia. Vaccines, 2020, 8, 719.	4.4	4
137	Reduction of Allergic Lung Disease by Mucosal Application of Toxoplasma gondii-Derived Molecules: Possible Role of Carbohydrates. Frontiers in Immunology, 2020, 11, 612766.	4.8	4
138	HERIZON: A phase 1B/2 open-label study of imu-131 HER2/neu peptide vaccine PLUS standard of care chemotherapy with randomization in phase 2 in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.. Journal of Clinical Oncology, 2021, 39, e16065-e16065.	1.6	4
139	Abstract CT107: A PHASE 1B/2 OPEN-LABEL STUDY WITH RANDOMIZATION IN PHASE 2 OF IMU-131 HER2/NEU PEPTIDE VACCINE PLUS STANDARD OF CARE CHEMOTHERAPY IN PATIENTS WITH HER2/NEU OVEREXPRESSING METASTATIC OR ADVANCED ADENOCARCINOMA OF THE STOMACH OR GASTROESOPHAGEAL JUNCTION. Cancer Research, 2021, 81, CT107-CT107.	0.9	4
140	Autochthonous Human Dirofilaria repens Infection in Austria. Acta Parasitologica, 2022, 67, 1039-1043.	1.1	4
141	Comprehensive results of a phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer. Annals of Oncology, 2019, 30, v495-v496.	1.2	3
142	Phase 2 clinical results: Chikungunya vaccine based on measles vector (MV-CHIK) induces humoral and cellular responses in the presence of pre-existing anti measles immunity. International Journal of Infectious Diseases, 2019, 79, 118.	3.3	3
143	Isolate-Based Surveillance of Bordetella pertussis, Austria, 2018â€“2020. Emerging Infectious Diseases, 2021, 27, 862-871.	4.3	3
144	Immunoregulation by microbes and parasites in the control of allergy and autoimmunity. , 2009, , 45-75.		3

#	Article	IF	Citations
145	Impaired mucosal immune response in vitamin A deficient rats immunized with oral cholera vaccine. Advances in Experimental Medicine and Biology, 1995, 371B, 1629-31.	1.6	3
146	Antibody Response in Bronchoalveolar Lavage and Bile in Rats after Aerosol Immunisation with an <i>Escheriehia coli</i> Strain Producing Ovalbumin. International Archives of Allergy and Immunology, 1993, 101, 254-259.	2.1	2
147	Different HBs Antibody versus Lymphoproliferative Responses after Application of a Monovalent (Hepatitis B) or Combined (Hepatitis A + Hepatitis B) Vaccine. International Archives of Allergy and Immunology, 2000, 123, 349-353.	2.1	2
148	Hitting the Mucosal Road in Tolerance Induction. Nestle Nutrition Workshop Series Paediatric Programme, 2009, 64, 63-74.	1.5	2
149	A phase Ib study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.. Journal of Clinical Oncology, 2019, 37, 4030-4030.	1.6	2
150	Editorial: Challenges in Vaccinology. Frontiers in Immunology, 2020, 11, 632537.	4.8	2
151	SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year. Frontiers in Medicine, 2022, 9, 822316.	2.6	2
152	The EFIS vaccination task force expert report. European Journal of Immunology, 2021, 51, 1023-1027.	2.9	1
153	P-159 HERIZON: Phase 2 part of the IMU-131 HER2/neu vaccine plus chemotherapy study randomized in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction. Annals of Oncology, 2021, 32, S154.	1.2	1
154	Reaktionen und Nebenwirkungen nach Impfungen: ErlÃuterungen und Definitionen in ErgÃnzung zum Ã–sterreichischen Impfplan. Intrinsic Activity, 2014, 2, e2.	0.0	1
155	A phase Ib/II open label study of IMU-131 HER2/Neu peptide vaccine plus cisplatin and either 5-fluorouracil or capecitabine chemotherapy in patients with HER2/Neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.. Journal of Clinical Oncology, 2019, 37, TPS176-TPS176.	1.6	1
156	Medical students' knowledge and attitudes regarding vaccination against measles, influenza and HPV. An international multicenter study. Journal of Preventive Medicine and Hygiene, 2020, 61, E181-E185.	0.9	1
157	Course of Fecal Calprotectin after mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Diseases. Vaccines, 2022, 10, 759.	4.4	1
158	Active immunization with immune checkpoint inhibitors-mimotope elicits strong anti-tumour effect against HER-2/neu-expressing tumours. Annals of Oncology, 2019, 30, v480.	1.2	0
159	Reduced antibody levels and high seronegativity rates against vaccine preventable diseases pose a risk factor for infections in patients with solid and hematologic cancers. Annals of Oncology, 2019, 30, v746.	1.2	0
160	Routine Adult Vaccines. , 2019, , 75-87.		0
161	Impfungen fÃ¼r MitarbeiterInnen des Gesundheitswesens: Empfehlungen als Erweiterung des Ã–sterreichischen Impfplans. Intrinsic Activity, 2014, 2, e5.	0.0	0
162	Reiseimpfungen mit spezieller Indikation: Gelbfieber, Tollwut, Japanische Enzephalitis, Typhus, Meningokokken. Intrinsic Activity, 2019, 7, e1.	0.0	0

#	Article	IF	Citations
163	Abstract CT059: A Phase Ib open label multicenter study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy shows safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced cancer of the stomach. , 2019, , .		0
164	Abstract 4110: Identification of PD1 B cell mimotopes with functional PD1-PDL1 blocking capacity: New strategy for cancer immunotherapy. , 2019, , .		0
165	Abstract 3151: Active immunization with PD1-derived mimotope-Combination immunotherapy against Her-2/neu-expressing tumors. , 2020, , .		0
166	22P Active immunization with a multi-peptide B cell vaccine, targeting trastuzumab and pertuzumab binding sites, prevents the formation of Her-2/neu-expressing lung metastases. Annals of Oncology, 2022, 33, S11-S12.	1.2	0
167	Abstract CT059: A Phase Ib open label multicenter study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy shows safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced cancer of the stomach. , 2019, , .		0
168	Abstract 4110: Identification of PD1 B cell mimotopes with functional PD1-PDL1 blocking capacity: New strategy for cancer immunotherapy. , 2019, , .		0